ePoster Submission
Submission deadline: Wednesday, 21 August 2019
Please note that abstracts accepted as "ePosters only" will be displayed on terminals during the congress. However they will not be presented at a specific session. In addition all ePosters will be available on the ECTRIMS Online Library.
For your references please find below the ePoster numbers.
ePoster numbers
| ePoster Number | Abstract Title | First Name | Last Name |
|---|---|---|---|
| EP1444 | Is the antibody titer really useful to verify the immunization of VZV Vaccine in MS patient treated with Fingolimod? | Signoriello | Elisabetta |
| EP1445 | Contribution of spinal cord lesions in diagnosing multiple sclerosis according to the McDonald 2017 criteria in patients with clinically isolated syndrome | María | Díaz Sánchez |
| EP1446 | Factors associated with time from symptom onset to definite MS diagnosis in a low prevalence country | Simón | Cárdenas-Robledo |
| EP1447 | New consensus diagnosis criteria of Neurosarcoidosis: Application in a French cohort of 35 patients | Clément | Richard |
| EP1448 | Acute inflammatory myelitis - a 10-year clinical review | Joana | Guimarães |
| EP1449 | Clinical Features to Aid in the Diagnosis of Acute Flaccid Myelitis versus Transverse Myelitis | Alfred | Balasa |
| EP1450 | MOG-IgG longitudinally extensive transverse myelitis in a patient with systemic lupus erythematosus | Philippe Antoine | Bilodeau |
| EP1451 | Severe demyelinating brain lesions in a patient with systemic mastocytosis: multiple sclerosis or brain mastocytosis? | Ysoline | Beigneux |
| EP1452 | Prevalence of anti-JC -virus among patients suffering from multiple sclerosis in Kazakhstan | Aksholpan | Sharapkhanova |
| EP1453 | Anti-MOG antibodies and neurofilament light chain serum levels in tumefactive Multiple Sclerosis: A longitudinal case report | Marianthi | Breza |
| EP1454 | Myelin oligodendrocyte glycoprotein antibody-associated disease in a multi-ethnic Canadian cohort | Helen Margot | Cross |
| EP1455 | Epidemiological, clinical, paraclinical and therapeutic characteristics of multiple sclerosis in childhood | Khaoula | Jemai |
| EP1456 | PANGAEA 2.0 EVOLUTION: state of the art multiple sclerosis patient management in daily clinical practice to identify key parameters for a more unified and early diagnosis of SPMS | Ulf | Schulze-Topphoff |
| EP1457 | Disability and walking speed are associated with quality of life in not active progressive MS: A baseline analysis of the SPI2 study | Bruce | Cree |
| EP1458 | Predictors of low quality of life at disease onset among a Peruvian sample of MS patients | Darwin | Vizcarra |
| EP1459 | Disability trajectories in relapsing-remitting multiple sclerosis | Tomas | Uher |
| EP1460 | Neuromyelitis optica spectrum disorder: is it the Aquaporin-4 autoantibodies (AQP-4 Ab) seropositive a different entity from AQP-4 negative patients? A Colombian perspective | Mariana | Gaviria |
| EP1461 | Mediterranean Diet assessment in Relapsing Remitting Multiple Sclerosis: a preliminary cross-sectional study in Italy | Riccardo | Giossi |
| EP1462 | Multiple sclerosis in Argentina: methodological and baseline data from the Argentinean MS Registry (RelevarEM) | Juan Ignacio | Rojas |
| EP1463 | Assessment of the Public Health Impact of Multiple Sclerosis (MS) on the patient´s perception in Spain | Ester | Moral Torres |
| EP1464 | Health related quality of life and perceived social support in French and Lebanese MS patients: a comparative study | Michella | Ibrahim |
| EP1465 | Clinical profile of elderly patients with multiple sclerosis in Colombia | Paola Andrea | Ortiz Salas |
| EP1466 | Influence of DMT exposure on relapse rates during pregnancy in patients with multiple sclerosis | Sandra | Raunegger |
| EP1467 | Racial and ethnic differences in multiple sclerosis hospitalizations in the United States from 2010 to 2016 | Tetine | Sentell |
| EP1468 | Fatigue and cognitive dysfunction in early multiple sclerosis: possible association with autonomic symptom burden? | Arianna | Sartori |
| EP1469 | Understanding The Patient Perspective: Living with Multiple Sclerosis (MS) and Managing MS Symptoms | Joanna | White |
| EP1470 | RISK FACTORS OF FALLS AND GAIT IMBALANCE: ASSOCIATION WITH COGNITIVE FUNCTIONS in MULTIPLE SCLEROSIS PATIENTS | Muhtesem | Gedizlioglu |
| EP1471 | Dissociation between indicators of cognitive status and neurophysiological response in patients with MS | Оlena | Mialovytska |
| EP1472 | Depression and multiple sclerosis: influence on cognitive performance | Eva | Fernandez-Diaz |
| EP1473 | Occurrence of epilepsy in MS patients - a retrospective study of two specialized centers in Northern Germany | Matthias | Grothe |
| EP1474 | Neuropsychological profile of relapsing remitting multiple sclerosis in Kerala, India, and correlation with lesion load | Sruthi S | Nair |
| EP1475 | The MRI-risk knowledge questionnaire 2.0 (MRI-RIKNO 2.0) - Assessment of MRI specific knowledge in people with multiple sclerosis and its association with emotions towards MRI | Insa | Schiffmann |
| EP1476 | Neural correlates of cognitive-motor dual tasks in multiple sclerosis: an fNIRS study | Ludovico | Pedullà |
| EP1477 | Gait performance in Timed 25 foot walk test and subjective perceived limitation of activities of daily living | Klara | Novotna |
| EP1478 | CCAS vs SDMT as a screening tool for cognitive impairment in cerebellar MS patients | Ines | Gonzalez- Suárez |
| EP1479 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | Bart | Van Wijmeersch |
| EP1480 | Reported Quality of Life in those on High Efficacy Compared to First Line Disease Modifying Therapies in a Community Cohort | Tamela | Stuchiner |
| EP1481 | Construct validity and test-retest reliability of the Swedish version of the Acceptance of Chronic Health Conditions Scale | Andreas | Wallin |
| EP1482 | Patients reported outcome measures from relapsing remitting people with Multiple Sclerosis on first line disease modifying therapies in a real world setting | Simona | Bonavita |
| EP1483 | Impact of multiple sclerosis upon employment status of the patients | Anna | Pokryszko-Dragan |
| EP1484 | Self-Management and Coping strategies in patients with Multiple Sclerosis; A Multicenter-prospective study | HÜSNÜ | Efendi |
| EP1485 | Patient reported fatigue and disability in multiple sclerosis: it matters how you ask and when you ask | Jared | Srinivasan |
| EP1486 | Cost-effectiveness review of prolonged release fampridine in managing walking impairment in a population with advanced multiple sclerosis | Rachel | Farrell |
| EP1487 | Low contrast visual acuity and ganglion cell layer thickness are promising outcome biomarkers after first event of acute demyelinating optic neuritis | Sylvia | Klineova |
| EP1488 | Left vs. right in optic neuritis: is there a more frequently affected eye? | Yavor | Yalachkov |
| EP1489 | Eye movement abnormalities: marker of cognitive dysfunction in Multiple Sclerosis ? | Saloua | Mrabet |
| EP1490 | The prevalence of autoimmune thyroid disease in patients newly diagnosed with multiple sclerosis | Maryam | Poursadeghfard |
| EP1491 | Anxiety in Argentinian patients with multiple sclerosis: prevalence and associated factors | Anibal | Chertcoff |
| EP1492 | Emergency medical care for multiple sclerosis in the Campania Region (South Italy) from 2015 to 2017 | Marcello | Moccia |
| EP1493 | Impact of systemic comorbidities on grey matter atrophy in Multiple Sclerosis | Ethel | Ciampi |
| EP1494 | Epilepsy and Multiple Sclerosis: A comorbidity in Argentinian cohort patients without progressive forms | Guido David | Vazquez |
| EP1495 | Nano hesperetin: improve myelin repair and ameliorate glial activation of optic chiasm in lysolecithin-induced focal demyelination model | Saeideh | Baradaran |
| EP1496 | Establishing the role of miR-150 in Multiple Sclerosis and experimental autoimmune encephalomyelitis | Eliane | Piket |
| EP1497 | Anti-IL-6 receptor antibody prevents blood-brain barrier disruption in mice with experimental autoimmune encephalomyelitis (EAE) | Kenichi | Serizawa |
| EP1498 | P2RX7 gene exonic variants in familial multiple sclerosis | Paloma | Montero-Escribano |
| EP1499 | Sequencing of AQP1, AQP4 and MOG genes in Spanish population with neuromyelitis optica spectrum disorders (NMOSD) | María | Díaz Sánchez |
| EP1500 | The role of CD44 in the development of inflammatory lesions in the central nervous system | Maria-Sophia | Stadler |
| EP1501 | Fluorescence Lifetime Imaging as a Method for B-Cell-Classification in MS Lesions of the Human Brain | Hanna Josephin | Eisenberg |
| EP1502 | Immunological Impact of Dietary Methionine Availability in Preclinical Models of Multiple Sclerosis | Victoria Hannah | Mamane |
| EP1503 | Multiparametric immunophenotyping of whole blood in IFNβ1a-treated multiple sclerosis patients | Priyanka | Devi-Marulkar |
| EP1504 | The influence of catecholamines on Th17-immune response in multiple sclerosis | Mikhail | Melnikov |
| EP1505 | BK Virus Can Be Neurotropic: A Rare Cause of PML | Cansu | Ayvacıoğlu |
| EP1506 | The role of diet related short chain fatty acids in multiple sclerosis. A pilot study | Laura | Moles Alegre |
| EP1507 | A higher intake of antioxidant from diet is associated with decreased odds of NMO-IgG seropositivity in neuromyelitis optica spectrum disorder patients | Nasim | Rezaeimanesh |
| EP1508 | Cerebrospinal fluid markers in patients with multiple sclerosis | Katerina | Bucilova |
| EP1509 | Early cognitive dysfunction as a marker of unfavorable course оf multiple sclerosis: prospective 12 years' study | Dmitry | Kasatkin |
| EP1510 | Early cognitive impairment in multiple sclerosis patients in relation to brain atrophy, Egyptian sample | Alaa Mohamed | Abou-Steit |
| EP1511 | Magnetic Resonance Spectroscopy: Correlates with DTI and Brain Atrophy in Multiple Sclerosis | Kain | Kyle |
| EP1512 | Macrophage failure to reach a pro regenerative state reflects multiple sclerosis severity | Jennifer | Fransson |
| EP1513 | Vitamin D - an effective antioxidant in an animal model of progressive Multiple Sclerosis? | Sonja | Hochmeister |
| EP1514 | Neurotrophic factors are required for neuronal regeneration induced by interleukin-10 | Sarah | Hirschberg |
| EP1515 | The importance of MRI pulse sequence selection in detecting brain hypointense lesions in multiple sclerosis. Relevance for the definition of “black holes” | Caterina | Lapucci |
| EP1516 | A Statistical Reference Percentile Chart for Evaluating Brain Atrophy in Multiple Sclerosis | Amir | Mazhari |
| EP1517 | Lateral ventricle volume change in Multiple Sclerosis: A preliminary study of brain atrophy using clinical routine MRI | Shmuel | Miron |
| EP1518 | Lesion volume and spatial mapping performance of automatic lesion segmentation by volBrain and Lesion growth algorithm in multiple sclerosis | Lin | Zhao |
| EP1519 | Preserved regional cortical volumes in multiple sclerosis patients with minimal disability compared to healthy volunteers | Michaela | Andelova |
| EP1520 | Microglial activation in the normal appearing white matter predicts later disease progression in multiple sclerosis | Marcus | Sucksdorff |
| EP1521 | Fully automated lesion segmentation using heavily trained 3D convolutional neural networks are equivalent to manual expert segmentations | Julia | Krüger |
| EP1522 | Regional Corpus Callosum Cross-sectional Area Atrophy In Multiple Sclerosis | Mikolaj | Pawlak |
| EP1523 | Volbrain: A useful brain segmentation software in Multiple Sclerosis | Fernando | Cortés-Enríquez |
| EP1524 | Snickers or Mars? A functional magnetic resonance imaging task on preference-based decision making in multiple sclerosis | Insa | Schiffmann |
| EP1525 | MRI of the optic nerve: Different characteristics of optic neuritis and optic nerve sheath meningioma | Achim | Gass |
| EP1526 | Optical Coherence Tomography in Multiple Sclerosis and Neuromyelitis-Optica | Doaa | Abdellatif |
| EP1527 | Peripapillary RNFL and macular volume measured with optical coherence tomography as possible biomarkers of ineffective disease activity control in very early RRMS patients | Silvia | Miante |
| EP1528 | The beneficial effects of higher vitamin B6 intake in cognitive function improvement among patients with neuromyelitis optica spectrum disorder | Nasim | Rezaeimanesh |
| EP1529 | Effect of Teriflunomide versus Dimethyl Fumarate on cognitive performance in multiple sclerosis patients: Real-world data | Daniela Noa | Zohar |
| EP1530 | Cognitive assessment and cytokine profile of multiple sclerosis patients presenting with only optic neuritis and myelitis | Erdem | Tüzün |
| EP1531 | Lipid-specific oligoclonal IgM bands and cognition in the early stages of multiple sclerosis | Clàudia | Coll Martinez |
| EP1532 | Longitudinal pilot study to evaluate the effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis | Anna | Gil-S |
| EP1533 | Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis | Matilde | Inglese |
| EP1534 | Cannabinoid receptors in multiple sclerosis: genetic association and gene expression in immune cells | Michael | Hecker |
| EP1535 | Serum glutamate and nitric oxide as markers of activity and relapses in multiple sclerosis | Amr Mohamed | Fouad |
| EP1536 | Isotope dilution ultra-high performance liquid chromatography/tandem mass spectrometry quantitative analysis of kynurenine pathway intermediates as potential biomarkers for multiple sclerosis in human serum and cerebrospinal fluid | Eva | Hényková |
| EP1537 | Using serum metabolomics to predict development of neutralising anti-drug antibodies in multiple sclerosis patients treated with IFNβ | Kirsty | Waddington |
| EP1538 | Th1-like Th17 cells as potential early biomarker of treatment response to Dimethyl Fumarate | Silvia | Presas-Rodríguez |
| EP1539 | Evidence of the Utility of CSF Neurofilament Light Chain Measurements in people with MS in Clinical Practice | Saúl | Reyes |
| EP1540 | Study of exosomes derived from activated platelets in Multiple Sclerosis relapse and remission paired patients | Jezabel | Varadé |
| EP1541 | Axonal damage of optic nerve correlates with physical and cognitive disability in multiple sclerosis | Simona | Petrescu |
| EP1542 | Association of kappa-free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis | Franziska | Bachhuber |
| EP1543 | High neurofilament light chain and high quinolinic acid levels in the CSF of patients with multiple sclerosis are independent predictors of active, disabling disease | Cecilia | Rajda |
| EP1544 | PANGAEA 2.0: effectiveness of fingolimod in patients with disease activity switching from other DMTs and different treatment frequencies | Ulf | Schulze-Topphoff |
| EP1545 | Fingolimod can suppress multiple sclerosis relapses without decreasing serum chemokine levels: implications for relapses after fingolimod discontinuation | Yusei | Miyazaki |
| EP1546 | RAM-589.555 decreases CNS-infiltrating immune cells and favors their anti-inflammatory cytokine profile in acute relapse EAE affected mice | Rina | Zilkha-Falb |
| EP1547 | Characteristics of multiple sclerosis patients treated with highly effective DMTs in a large real-world cohort | Carrie | Hersh |
| EP1548 | Case Series: Central Nervous System Demyelination in the Setting of Tumor Necrosis Factor-α (TNF- α) Blockers: Uncommon Presentations and Therapeutic Strategies | Sharon | Stoll |
| EP1549 | Efficacy and safety of teriflunomide in patients switching from other DMTs in the real-world TAURUS-MS I study | Thorsten | Rosenkranz |
| EP1550 | Post-hoc Analysis to Evaluate the Effects of Subcutaneous Interferon β-1a in Subgroups of Patients from the PRISMS Study with Early Onset vs Late Onset Disease | M.S. | Freedman |
| EP1551 | Assessment of differential effects of ENX-201 versus placebo, free methylprednisolone and/or non-targeted liposomes in healthy rats | Pieter Jaap | Gaillard |
| EP1552 | Glatiramer Acetate Depot (extended-release) Accumulated Safety Data in Relapsing Remitting Multiple Sclerosis & Primary Progressive Multiple Sclerosis phase IIa studies | Arnon | Karni |
| EP1553 | Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results From the Phase 3 EVOLVE-MS-1 Study | Florian | Then Bergh |
| EP1554 | Rituximab treatment of multiple sclerosis in the Hospital District of Southwest Finland | Marjo | Nylund |
| EP1555 | 20-week results of the phase 3, multicenter, double-blind, placebo-controlled study of the original pegylated interferon beta-1a drug in patients with remitting multiple sclerosis | Arina | Zinkina-Orikhan |
| EP1556 | Non-interventional, prospective study CLADQoL (CLADribine Tablets - evaluation of Quality of Life), data extraction March 2019 | Iris-Katharina | Penner |
| EP1557 | Real world Efficacy and Safety Profile of Ocrelizumab therapy in patients with Multiple Sclerosis | Vince | Tran |
| EP1558 | Peginterferon beta-1a every 2 weeks demonstrates better clinical outcomes than glatiramer acetate 40 mg/mL 3 times a week in patients with relapsing-remitting multiple sclerosis using a matching-adjusted indirect comparison of phase 3 trials | Thomas | Scott |
| EP1559 | Assessing the Long-term Outcomes of Ocrelizumab Treatment in Germany - CONFIDENCE Baseline Characteristics | Petra | Dirks |
| EP1560 | Regulation of the IFNß activity in MS patients via alternative splicing: soluble isoform of IFNß receptor | Begoña | Oliver-Martos |
| EP1561 | Multiple Sclerosis Patients Initiating Dimethyl Fumarate Versus Fingolimod in the Real-World Setting Have Baseline Characteristics Associated with Worse Clinical Prognosis | Carrie | Hersh |
| EP1562 | Concurrent autoimmune hemolytic anemia and multiple sclerosis relapse in the presence of aquaporin-1 antibodies, following treatment with Alemtuzumab | John | Tzartos |
| EP1563 | Alemtuzumab as alternative to patients with relapsing-remitting multiple sclerosis who failed to Fingolimod | Ana Mª | López Real |
| EP1564 | Human chorionic gonadotrophin: the potential link between pregnancy improvement in the context of Multiple Sclerosis | Lorena Vanesa | Juriol |
| EP1565 | Safety and effectiveness of natalizumab in a real-world multiple sclerosis portuguese population | Marta | Sequeira |
| EP1566 | Efficacy of Mitoxantrone in Aggressive disease in North Indian MS patients | Dheeraj | Khurana |
| EP1567 | Natalizumab is an appropriate treatment choice in rapidly evolving Balo's concentric sclerosis | Marc | Edwards |
| EP1568 | Real world efficacy and safety of teriflunomide in multiple sclerosis: An observational study with four years follow-up | Cavit | Boz |
| EP1569 | Leptomeningeal contrast enhancement disappeared on therapy with Natalizumab in multiple sclerosis: case reports | Gleb | Makshakov |
| EP1570 | A real-world, single-center, retrospective cohort analysis of alemtuzumab clinical and safety outcomes in persons with relapsing multiple sclerosis | Christopher | Hemond |
| EP1571 | Alemtuzumab protects regional and global brain volumes in MS. A single subject analysis | Alaleh | Raji |
| EP1572 | Long term, registry-based, prospective, post-authorization safety study evaluating adverse events of special interest in patients with highly active relapsing multiple sclerosis newly started on oral cladribine − CLARION | Helmut | Butzkueven |
| EP1573 | Long-term disease stability assessed by the Expanded Disability Status Scale in patients treated with Cladribine Tablets in the CLARITY and CLARITY Extension studies | Gavin | Giovannoni |
| EP1574 | One Year Prospective Follow up of Fluvastatin as an Add-on Disease Modifying Therapy in Established Relapsing Multiple Sclerosis | Nazaneen | Al-Ajlan |
| EP1575 | Machine Learning Analysis of Motor Evoked Potential Time Series to Predict Disability Progression in Multiple Sclerosis | Thijs | Becker |
| EP1576 | Early differentiating characteristics of clinically stable patients on low efficacy immunomodulatory treatment over long-term follow-up | Tereza | Hrnciarova |
| EP1577 | Cladribine tablets: Observational evaluation of effectiveness, safety, and patient reported outcomes in suboptimally controlled patients previously taking injectable disease-modifying drugs for relapsing forms of multiple sclerosis (CLICK-MS) | Augusto A. | Miravalle |
| EP1578 | Long-term clinical disease activity and adverse events in teriflunomide-treated patients following conversion to clinically definite multiple sclerosis in the TOPIC study | Luwig | Kappos |
| EP1579 | Cognitive functions over the course of 5 years in multiple sclerosis patients treated with disease modifying therapies | Serkan | Ozakbas |
| EP1580 | Repigmentation of vitiligo lesions in a patient treated with Teriflunomide: a case report | Pablo | Baena |
| EP1581 | Alemtuzumab-related cytokine release syndrome associates with patient's age and previous disease-modifying treatments | Francesca | Rinaldi |
| EP1582 | Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: How risky is Fingolimod-induced lymphopenia? | Serkan | Ozakbas |
| EP1583 | Neutropenia associated with Ocrelizumab in a Multiple Sclerosis Progresive patient | Virginia | Meca-Lallana |
| EP1584 | Alemtuzumab-induced thyroid disease: observational data from an Italian cohort of patients | Lucia | Moiola |
| EP1585 | Natalizumab: Extended versus Standard Interval Dosing in the real world | Bert | Wagner |
| EP1586 | Adverse effects of monoclonal antibodies in patients with multiple sclerosis: a real world experience | Meltem | Baklan |
| EP1587 | Applying machine learning algorithms to evaluate the association between emotional expressions and therapeutic inertia among neurologists who care for people living with multiple sclerosis | Gustavo | Saposnik |
| EP1588 | Effects of multi-focal intermittent theta burst stimulation on spasticity and endurance in patients with progressive multiple sclerosis | Hatem | Shehata |
| EP1589 | Retrospective analysis of respository corticotropin injection use for the prevention of infusion reactions related to alemtuzumab administration in Multiple sclerosis patients | Christen | Kutz |
| EP1590 | Number-needed-to-treat analysis and risk-benefit assessment of ozanimod compared with first-line disease-modifying therapies for relapsing-remitting multiple sclerosis | Jinender | Kumar |
| EP1591 | Safety and tolerability data of a new brand-generic product of Teriflunomide in Iranian relapsing-remitting multiple sclerosis patients: an observational cohort study | Roya | Abolfazli |
| EP1592 | A triple-blind, randomized controlled trial of Saffron in cognitive function of Multiple Sclerosis patients | Amir Reza | Azimi |
| EP1593 | Year 1 Performance of adveva®, a Patient Support Programme (PSP) for patients taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK) | Kate | Morgan |
| EP1594 | Evaluation of perception of risk and satisfaction in second-line treatments for MS | Ines | González-Suárez |
| EP1595 | Improving Cognition in People with Progressive Multiple Sclerosis: A Multi-Arm, Randomized, Blinded, Sham-Controlled Trial of Cognitive Rehabilitation and Aerobic Exercise (COGEx) | Anthony | Feinstein |
| EP1596 | A patient-centred evaluation of thermal resilience practices in temperature-sensitive people with Multiple Sclerosis | Aikaterini | Christogianni |
| EP1597 | High-resolution whole-body mapping of warm and cold thermosensitivity in people with multiple sclerosis | Aikaterini | Christogianni |
| EP1598 | Association between fatigue and upper extremity function in persons with multiple sclerosis | Asiye Tuba | Özdoğar |
| EP1599 | Assessment of the effectiveness of the Exoatlet exoskeleton for the rehabilitation of the patients with multiple sclerosis | Victoria | Lizhdvoy |
| EP1600 | Effect of obesity on walking and balance control in people with multiple sclerosis | Turhan | Kahraman |
| EP1601 | Fatigue Relief in Multiple Sclerosis (FaReMuS): a single-center, cross over, double blinded and sham controlled study in anodal bilateral primary somatosensory areas transcranial direct current stimulation in Multiple Sclerosis | Elvira | Sbragia |
| EP1602 | Investigation of long-term potentiation- and depression-induced tau phosphorylation in rats with starch based sugar | Yeliz | Tasci |
| EP1603 | Effect of endurance training on serum brain-derived neurotrophic factor (BDNF) response in multiple sclerosis | Seyed Massood | Nabavi |